{
    "nctId": "NCT01816594",
    "briefTitle": "NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer",
    "officialTitle": "NeoPHOEBE: Pi3k Inhibition in Her2 OverExpressing Breast cancEr: A Phase II, Randomized, Parallel Cohort, Two Stage, Double-blind, Placebo-controlled Study of Neoadjuvant Trastuzumab Versus Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive, PIK3CA Wild-type and PIK3CA Mutant Primary Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "HER2-positive Newly Diagnosed, Primary Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 50,
    "primaryOutcomeMeasure": "Pathological Complete Response (pCR) Rate at the Time of Surgery - All Participants",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patient had provided a signed study ICF prior to any screening procedure\n* Patient was a female \u2265 18 years of age\n* Patient has an ECOG performance status of 0-1\n* Patient has a unilateral (multifocal or multicentric disease allowed), histologically confirmed, newly diagnosed early breast cancer \\>2cm by clinical examination and/or \\>1.5 cm confirmed by ultrasound or by MRI\n* Patient has tumor tissue available for central review of ER, HER2 and PI3K status with centrally confirmed HER2-positive disease and known PI3KCA mutation status\n* Patient has adequate bone marrow, renal and liver function\n* Patient is able to swallow and retain oral medication\n\nExclusion Criteria:\n\n* Patient has received prior systemic treatment for currently diagnosed disease\n* Patient has a known contraindications, hypersensitivity or intolerance to trastuzumab, paclitaxel or products containing cremophor\n* Patient has bilateral breast cancer or metastatic disease or inflammatory breast cancer\n* LVEF below 50% as determined by MUGA scan or ECHO\n* Patient has active cardiac disease or a history of cardiac abnormalities as defined in the protocol\n* Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BKM120\n* Patient is currently receiving warfarin or other coumarin derived anti-coagulants\n* Patient is currently receiving chronic treatment with corticosteroids or another immunosuppressive agents (standard premedication for paclitaxel and local applications allowed)\n* Patient is currently receiving treatment with drugs known to be strong inhibitors or inducers of CYP3A\n* Patient has certain scores on an anxiety and depression mood questionnaires\n* Pregnant or nursing (lactating) women or patients not willing to apply apply highly effective contraception as defined in the protocol",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}